Functional Personalized Treatment of Metastatic Porocarcinoma

Abstract

SummaryMetastatic porocarcinomas (PC) have high mortality rates of 70%. PC is extremely rare, accounting for 0.01% of malignant cutaneous neoplasms, precluding the possibility of conducting clinical trials to evaluate treatment. Pathogenesis and clinical management of PC remain largely unknown Surgical resection of localized PC remains the mainstay of treatment. There are no effective agents for unresectable PC. Comprehensive genomic profiling did not yield any actionable genomic aberrations in our patient with metastatic PC.Ex vivodrug testing predicted pazopanib efficacy and treatment elicited remarkable clinicoradiological response. A functional precision medicine approach may be effective for the treatment of rare cancers.